319 related articles for article (PubMed ID: 22294631)
1. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
Beyer C; Zenzmaier C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Pachowsky ML; Friebe A; Sandner P; Distler O; Schett G; Berger P; Distler JH
Ann Rheum Dis; 2015 Jul; 74(7):1408-16. PubMed ID: 24567525
[TBL] [Abstract][Full Text] [Related]
3. Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
Matei AE; Beyer C; Györfi AH; Soare A; Chen CW; Dees C; Bergmann C; Ramming A; Friebe A; Hofmann F; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2018 Mar; 77(3):459. PubMed ID: 29311148
[TBL] [Abstract][Full Text] [Related]
4. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
5. Activation of pregnane X receptor inhibits experimental dermal fibrosis.
Beyer C; Skapenko A; Distler A; Dees C; Reichert H; Munoz L; Leipe J; Schulze-Koops H; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2013 Apr; 72(4):621-5. PubMed ID: 23291432
[TBL] [Abstract][Full Text] [Related]
6. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
8. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
10. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
11. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.
Krönke G; Reich N; Scholtysek C; Akhmetshina A; Uderhardt S; Zerr P; Palumbo K; Lang V; Dees C; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1081-7. PubMed ID: 22267335
[TBL] [Abstract][Full Text] [Related]
12. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
13. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
14. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.
Masuyama H; Tsuruda T; Sekita Y; Hatakeyama K; Imamura T; Kato J; Asada Y; Stasch JP; Kitamura K
Hypertens Res; 2009 Jul; 32(7):597-603. PubMed ID: 19424280
[TBL] [Abstract][Full Text] [Related]
15. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf J; Weigand S; Alonso-Alija C; Bischoff E; Feurer A; Gerisch M; Kern A; Knorr A; Lang D; Muenter K; Radtke M; Schirok H; Schlemmer KH; Stahl E; Straub A; Wunder F; Stasch JP
ChemMedChem; 2009 May; 4(5):853-65. PubMed ID: 19263460
[TBL] [Abstract][Full Text] [Related]
16. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
[TBL] [Abstract][Full Text] [Related]
19. Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.
Stegemann A; Sindrilaru A; Eckes B; del Rey A; Heinick A; Schulte JS; Müller FU; Grando SA; Fiebich BL; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2013 Mar; 65(3):792-804. PubMed ID: 23440693
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
Stasch JP; Schlossmann J; Hocher B
Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
